<DOC>
	<DOC>NCT00550095</DOC>
	<brief_summary>This study is designed to assess the efficacy of the different dosage forms of Valsartan[80, 160, and 320 mg] in reducing microalbuminuria/proteinuria in hypertensive patients with type 2 diabetes.</brief_summary>
	<brief_title>To Assess the Effects of Valsartan on Albuminuria/Proteinuria in Hypertensive Patients With Type 2 Diabetes Mellitus</brief_title>
	<detailed_description />
	<mesh_term>Diabetes Mellitus</mesh_term>
	<mesh_term>Diabetes Mellitus, Type 2</mesh_term>
	<mesh_term>Proteinuria</mesh_term>
	<mesh_term>Albuminuria</mesh_term>
	<mesh_term>Valsartan</mesh_term>
	<criteria>Males or females aged 35 to 75. Type 2 diabetes mellitus (DM) patients coupled with hypertension [sitting systolic blood pressure (SSBP) 140179 mm Hg and/or SDBP 90109 mm Hg]. Urinary albumin creatinine Ratio (UACR)) indicating microalbuminuria/proteinuria [301000 mg/g or 2.525 mg/mmol] Body mass index (BMI) &lt;40 kg/m2 Patients who will sign an informed consent. Exclusion Criteria Type 1 DM All causes of secondary diabetes mellitus Women of childbearing potential who refuse to use contraception. Pregnant or lactating females. Severe hypertension [SSBP&gt; 180 mmHg, sitting diastolic blood pressure (SDBP) &gt; 110 mmHg ] Patients who are on combo therapy to control BP Patients who are already on Valsartan. Hypersensitivity to Valsartan. Renal artery stenosis [ unilateral or bilateral] Patients taking Î² blockers, (Angiotensin Converting Enzyme Inhibitor (ACEI) or spironolactone Heart Failure History of myocardial infarction, Percutaneous Transluminal Coronary Angioplasty(PTCA) or cerebrovascular accident within the preceding 3 months. Creatinine levels &gt; 1.4 mg/dl [ 0.07mmol/l]. Liver enzymes &gt; 2 times Upper Limit of the Normal Range(ULN). Diabetic ketoacidosis (DKA) within the last 6 months. Presence of diabetic neuropathy or retinopathy. Diabetic foot complications. Presence of infection at time of screening. Hyperkalemia (serum K+ &gt; 5.5 mmol/L)</criteria>
	<gender>All</gender>
	<minimum_age>35 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>February 2017</verification_date>
	<keyword>Microalbuminuria/proteinuria</keyword>
	<keyword>hypertensive patients with type 2 diabetes</keyword>
	<keyword>Valsartan</keyword>
	<keyword>microalbuminuria/proteinuria in hypertensive patients with type 2 diabetes</keyword>
</DOC>